[Bio Story]②Prostate Cancer Drug Topline Results Imminent... "Ultimate Goal Is the U.S. Market"
Jae-Yoon Ji, CEO of FutureChem, Interview Part 2
All Eyes on U.S. Phase 2a Clinical Results
"Break-Even Expected Next Year"
Jae-Yoon Ji, CEO of FutureChem, identified the most pivotal moment for the company this year as the release of Phase 2a clinical trial results for the prostate cancer therapeutic 'FC705' in the United States. The company is scheduled to receive topline data from its contract research organization (CRO) in mid-October, which will be released immediately, with the final report expected by the end of the year.
FC705 is a therapeutic agent combining a compound that binds to prostate-specific membrane antigen (PSMA)—which is overexpressed on the surface of prostate cancer cells—with the radioactive isotope Lutetium-177. When injected intravenously, the compound circulates through the bloodstream, seeks out cancer cells, and binds to them. The beta rays emitted in this process destroy the DNA of the cancer cells. The target patients are those with metastatic castration-resistant prostate cancer who no longer respond to surgery or chemotherapy.
The frontrunner among RPT drugs is Novartis' prostate cancer therapeutic, Pluvicto. Approved in the United States in 2022, Pluvicto, along with Lutathera, a neuroendocrine tumor treatment, generated $2.8 billion (about KRW 4 trillion) in revenue, opening up the market. Unlike Pluvicto, which is administered in a 200 mCi dose per session, FC705 is designed for a 100 mCi dose. This means it aims to achieve equivalent efficacy with half the radioactivity. On August 20, CEO Ji explained, "In the U.S. clinical trial, even after the attending physician reduced the second dose to 80 mCi at their discretion, a complete response was observed."
Dae-Yoon Ji, CEO of Futurechem, is being interviewed by our publication at the headquarters in Seongdong-gu, Seoul. Photo by Jung-Yeon Park
View original imageThe reason why major global pharmaceutical companies are awaiting the U.S. data is the limited scale of clinical trials in Korea. The Phase 1 and Phase 2 studies conducted in Korea involved only around 30 and 20 patients, respectively, resulting in small sample sizes. According to CEO Ji, "Given the low patient numbers, it seems they deem the U.S. data essential for certainty. If the results are comparable to or better than those in Korea, discussions on technology transfer will move forward in earnest." He further stressed, "From a scientist's perspective, before that of a businessperson, there isn't a scenario where this data turns out poorly."
"FutureChem: The Only Company with Both Diagnostic and Therapeutic Agents, Confident in the Global Market"
CEO Ji's ultimate goal is the U.S. market. Last year, sales from prostate cancer diagnostic and therapeutic agents in the United States each nearly reached KRW 3 trillion, and diagnostic agent prices are known to be more than ten times higher than in Korea. He stated, "Earlier this month, a company focusing primarily on diagnostic agents was acquired for KRW 11 trillion. We are essentially the only company with both diagnostic and therapeutic agents, so if the therapeutic results are also favorable, our standing as a company will fundamentally change."
The groundwork for global expansion is being laid first in Asia. On July 22, FutureChem signed an exclusive license and supply-distribution agreement for its prostate cancer diagnostic agent, ProstaView (FC303), with Hanoi Isotope Center (HIC), a subsidiary of the Vietnam Atomic Energy Institute (VINATOM). The agreement includes a USD 100,000 upfront payment, 15% royalties on local net sales, and exclusive supply of dedicated cassettes, precursors, and reagent kits necessary for manufacturing. Previously in May, FutureChem signed a supply contract for ProstaView with TMI in Indonesia, and last month, an exclusive supply agreement with Shreeji Imaging in India for its Alzheimer’s diagnostic agent, Alzaview.
What makes these agreements unique is that they are not simple export deals but involve establishing production systems locally. What FutureChem provides to its local partners is not the finished drug but the methods for manufacturing it. The company transfers manufacturing technology and quality control standards, supports partners with documentation needed for local regulatory approval, and the partners then produce the drugs themselves in facilities equipped with automatic synthesizers for distribution to hospitals within their countries. In this process, FutureChem exclusively supplies essential raw materials and proprietary consumables and receives a royalty based on a percentage of sales.
The main advantage of this model is recurring revenue. Because the consumables must be replaced each time new drugs are produced, FutureChem’s sales grow in direct proportion to increased local production. CEO Ji compared this to the McDonald’s business model, where the standardized process defined by headquarters ensures consistent products at any franchise location.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
On August 18, FutureChem announced that its consolidated sales for the first half of the year reached KRW 10.63 billion, marking a 22.0% year-on-year increase. This growth was driven by increased sales of radiopharmaceutical products and higher affiliate revenue. However, operating loss expanded to KRW 5.43 billion due to the burden of R&D expenses. CEO Ji said, "When we went public in 2016, sales were KRW 1.6 billion, but they climbed to KRW 18.6 billion last year. We project that sales will surpass KRW 25 billion this year and expect to reach the break-even point by next year."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.